| Description | The antibody PDI 222 is a neutralizing antibody against SARS-CoV-2 Spike S1, derived from human. This antibody maintains broad recognition of VOCs and potent neutralization of B.1.351. Its binding epitope centered on the RBD residue N487 overlapping the ACE2 interaction site. It has been detected using Enzyme-linked immunosorbent assay, Bio-layer interferometry and Neutralization assay. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 (B.1.351) |
| Epitope | An epitope near the E484 and K417 residues |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| Application Notes | This antibody has been tested by ELISA, Bio-layer interferometry (BLI) and Neutralization assay. ELISA: 5 μg/mL with a serial 1:2.5 dilution Bio-layer interferometry (BLI): 5 μg/mL Neutralization assay: The IC50 value of PDI 222 against SARS-CoV-2 is 0.005 μg/mL. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
